The wireless patch-type heart monitoring device Kardiobeat.ai, developed and introduced globally by Medicalgorithmics, has received certification from the Israeli Ministry of Health. Approval for the use of Kardiobeat.ai in Israel strengthens the presence of the medtech company, part of the sWIG80 index, in the Israeli market and will enable the commercial implementation of the Kardiobeat.ai Holter patch for clients. The company’s management expects that once SysteMedic, Medicalgorithmics’ exclusive partner in Israel, reaches full operational scale, the company will be able to generate around PLN 5 million in annual revenue from this market starting in 2026.
Kardiobeat.ai is a wireless “patch-wearable” device for ECG heart monitoring. The introduction of this client-desired solution in March of last year opened the door for Medicalgorithmics to enter the market for patient-friendly patch-Holter solutions, which allowed the company to expand its product portfolio. The solution originates from Livetec Ingenieurbüro GmbH (Livetec) – a German manufacturer of medical equipment used in the diagnosis of heart diseases. The partner is responsible for producing a small, wireless, three-channel offline heart monitoring device integrated with Medicalgorithmics’ diagnostic platform and artificial intelligence algorithms. The company distributes the product globally under the Kardiobeat.ai brand.
“The registration in Israel will allow us to establish a significant position in this market. We are already actively supporting our Israeli partner SysteMedic in ongoing presentations and pilot projects of our technology, making our product offering recognizable and desirable. As a result, and thanks to the certification obtained, we expect a gradual increase in revenues from Israel soon. We believe that, after fully establishing our presence in this market through our exclusive partner, revenues could eventually reach around PLN 5 million annually,” says Maciej Gamrot, CFO of Medicalgorithmics.
The certification of Kardiobeat.ai in Israel by Medicalgorithmics is the latest in a series of certifications recently obtained by the Polish medtech company. In mid-October of last year, Medicalgorithmics completed the CE certification process for its VCAST software, which is used for non-invasive coronary artery disease diagnostics. Obtaining the certificate opens up the possibility for the company to commercialize the technology in the EU and selected countries outside Europe. On October 24th of last year, Medicalgorithmics’ new cloud platform for arrhythmia diagnostics, the DeepRhythm Platform (DRP), received Health Canada registration for use in Canada. This platform is integrated with the latest generation of proprietary DRAI artificial intelligence algorithms, which had received registration in Canada three weeks earlier. Moreover, at the beginning of December last year, the Warsaw Stock Exchange-listed medtech expanded the registration of its DeepRhythmAI (DRAI) algorithms with the U.S. FDA to include a new category for ambulatory telemetry devices. Under the updated registration, DRAI can be used for the analysis of ECG data in ambulatory telemetry (product code QYX).